ReviewFrontiers in pharmacology2018

Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.

Hooi Hooi Ng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.